Innovative Funding Trends And Models</a>, Roche and IQVIA has jointly published a new white paper that aims to continuously enrich the discussion on the improvement of the rare disease funding environment. It will describe the challenges with rare disease access and funding as well as provide a deep dive into the significant progress in the rare disease funding and access landscape shown in twelve Lower Middle-Income Countries (LMICs). Finally, the paper also provides suggestions on three strategic imperatives for countries to improve their rare disease environment.</p>" /> Innovative Funding Trends And Models</a>, Roche and IQVIA has jointly published a new white paper that aims to continuously enrich the discussion on the improvement of the rare disease funding environment. It will describe the challenges with rare disease access and funding as well as provide a deep dive into the significant progress in the rare disease funding and access landscape shown in twelve Lower Middle-Income Countries (LMICs). Finally, the paper also provides suggestions on three strategic imperatives for countries to improve their rare disease environment.</p>" />
WHITE PAPER
Catalyzing Sustainable Funding for Rare Diseases
Aug 07, 2023

400 million patients worldwide are affected by over 7000 different types of rare diseases. More countries are now recognising the need for patients with rare diseases to have access to care by exploring alternative funding methods for rare diseases.

In continuation to our series of Innovative Funding Trends And Models, Roche and IQVIA has jointly published a new white paper that aims to continuously enrich the discussion on the improvement of the rare disease funding environment. It will describe the challenges with rare disease access and funding as well as provide a deep dive into the significant progress in the rare disease funding and access landscape shown in twelve Lower Middle-Income Countries (LMICs). Finally, the paper also provides suggestions on three strategic imperatives for countries to improve their rare disease environment.

Contact Us